

IN THE CLAIMS

1. (Currently Amended) ~~The use of cysteine and/or cystine to prepare oral medicinal products for the prevention and treatment of A method for preventing or treating oxidative stress resulting from haemodialysis treatment in patients suffering from chronic kidney failure or for the treatment and prevention of acute or chronic kidney diseases or of End-Stage Renal Disease which comprises administering to a patient in need thereof a therapeutically effective amount of a compound selected from the group consisting of cystine, cysteine and mixtures thereof.~~
2. (Currently Amended) The use method according to claim 1, for the prevention and treatment of oxidative stress resulting from haemodialysis treatment in patients suffering from chronic kidney failure.
3. (Currently Amended) Use A method as claimed in claim 1 [[or 2]], wherein the cystine and/or cysteine is administered in unit doses ranging from 200 to 1000 mg.
4. (Currently Amended) Use Method as claimed in claim 1, [[2 or 3,]] wherein the cystine and/or cysteine is administered before and/or after haemodialysis treatment.
5. (Currently Amended) A pharmaceutical compositions composition for oral administration for the prevention and treatment of oxidative stress resulting from haemodialysis treatment in patients suffering from chronic kidney failure or for the treatment and prevention of acute or chronic kidney diseases, containing cysteine or cystine as active constituent.

6. (Previously Presented) A method for the prevention and treatment of oxidative stress resulting from haemodialysis in patients suffering from chronic kidney failure comprising the administration to said patient from 200 to 1000 mg of cystine and/or cysteine orally before and/or after the haemodialysis treatment.

7. (Previously Presented) A method for the prevention and treatment of patients suffering from acute or chronic kidney failure comprising the oral administration to said patient from 200 to 1000 mg of cystine and/or cysteine.

8. (Previously Presented) A method for the prevention and treatment of patients suffering from End-Stage Renal-Disease comprising the oral administration to said patient from 200 to 1000 mg of cystine and/or cysteine.